DESKi Closes $6M Seed Round to Bring AI-Powered Heart Scans to Market
BORDEAUX, France–DESKi, a healthtech company developing AI-powered diagnostic tools in collaboration with clinicians and researchers, has announced the close of a $6 million seed round. The funding will support the U.S. and global market launch of its FDA-approved cardiac imaging software, HeartFocus.
The seed round was led by Racine², an impact-focused fund managed by Serena and Makesense, with participation from BNP Paribas Développement, Épopée Gestion, Good Only Ventures, Better Angle, and NACO, the Nouvelle-Aquitaine regional fund advised by M Capital. This group of leading European health and impact investors brings not only capital but deep alignment with DESKi’s vision to democratize access to early, AI-enabled cardiac care on a global scale.
“This funding moves us one step closer to a world where early heart disease detection is possible at any point of care,” said Dr. Bertrand Moal, MD, PhD, CEO and co-founder of DESKi. “It allows us to continue improving HeartFocus and ensures that more providers can access the tools they need to deliver life-saving diagnoses.”
Heart disease remains the leading cause of death in the U.S. and around the world, yet access to echocardiography is often limited by a shortage of trained specialists. HeartFocus bridges this gap with real-time AI guidance that enables any healthcare professional to perform cardiac ultrasounds after just a few hours of training, making early diagnosis possible even in primary care, rural clinics, and other resource-limited settings.
“With HeartFocus, DESKi is tackling one of the most urgent challenges in healthcare: how to make life-saving diagnostics available far beyond the walls of a hospital,” said Léa Zaslavsky, Partner at Racine². “We are proud to lead this round and support the company’s evolution from clinical validation to real-world impact.”
Other investors also expressed their support for the technology. Sophie Pierrin Lepinard, Director of Partnerships at BNPParibas Développement, said, “We invest in solutions that improve the patient journey for better care at better costs. We believe HeartFocus is uniquely positioned to transform how cardiovascular disease is detected and managed worldwide, with faster access.”
Camille Le Roux Larsabal, VC Partner at Épopée Gestion, added, “Épopée is honored to support this milestone and contribute to the international expansion of a high-impact ultrasound solution.”
HeartFocus is a revolutionary, AI-driven heart exam software that empowers any healthcare professional to perform world-class echos from any device, anywhere. Created in 2023 by French brothers Bertrand and Olivier Moal, HeartFocus leverages proprietary algorithms trained on over 10 million data points and validated through clinical trials.
For more information, visit www.heartfocus.ai.
